title: Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin.
abstract: We evaluated the DTI changes in the deep gray nuclei and dorsal brain stem, which demonstrated abnormal T2 and/or diffusion signal intensity, in 6 patients with infantile spasm treated with vigabatrin compared with 6 age-matched controls. Regions of interest were placed in the globi pallidi, thalami, and dorsal brain stem; FA, trace, D(‖), and D(⊥) were measured. Patients on vigabatrin had significantly lower FA in both globi pallidi (P = .01) and the dorsal brain stem (P < .01), significantly lower trace in both globi pallidi (P = .01) and the thalami (P = .02 and .01 for right and left, respectively), and significantly lower D(‖) in both globi pallidi (P ≤ .01), the thalami (P < .01), and the dorsal brain stem (P = .03). There were no significant differences in D(⊥) of the globi pallidi, thalami, or dorsal brain stem in patients compared with controls. The findings suggest that axonal changes play a greater role in the observed abnormal signal intensity, with lesser contribution from myelin changes.
authors.affiliation: Department of Diagnostic Imaging, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: G N
authors.initials: GN
authors.lastname: Simao
authors.forename: S
authors.initials: S
authors.lastname: Zarei Mahmoodabadi
authors.forename: O C
authors.initials: OC
authors.lastname: Snead
authors.forename: C
authors.initials: C
authors.lastname: Go
authors.forename: E
authors.initials: E
authors.lastname: Widjaja
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001933:Brain Stem / Q000187:drug effects* / Q000473:pathology*; D020833:Diffuse Axonal Injury / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D013036:Spasms, Infantile / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D020888:Vigabatrin / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin
references.citation: Exp Neurol. 1997 Apr;144(2):400-5
references.pmid: 9168839
references.citation: Neuroimage. 2004 Aug;22(4):1767-74
references.pmid: 15275932
references.citation: Br J Clin Pharmacol. 1989;27 Suppl 1:47S-52S
references.pmid: 2757909
references.citation: Epilepsy Res. 1994 May;18(1):57-66
references.pmid: 8088257
references.citation: J Child Neurol. 2009 Mar;24(3):305-15
references.pmid: 19258289
references.citation: Epilepsia. 1995 Jan;36(1):93-100
references.pmid: 8001516
references.citation: Epilepsia. 2010 Jul;51(7):1297-304
references.pmid: 20384718
references.citation: J Child Neurol. 2009 Dec;24(12):1543-6
references.pmid: 19773459
references.citation: Epilepsia. 2009 Feb;50(2):195-205
references.pmid: 19054414
references.citation: Magn Reson Med. 1996 Oct;36(4):627-31
references.pmid: 8892217
references.citation: Epilepsia. 2009 Feb;50(2):184-94
references.pmid: 18783433
references.citation: Neuroimage. 2003 Nov;20(3):1714-22
references.pmid: 14642481
references.citation: J Magn Reson B. 1996 Jun;111(3):209-19
references.pmid: 8661285
references.citation: Epilepsia. 2009 Feb;50(2):163-73
references.pmid: 19230067
references.citation: Epilepsia. 2000 Jun;41(6):655-65
references.pmid: 10840396
references.citation: Neuroimage. 2002 Nov;17(3):1429-36
references.pmid: 12414282
references.citation: Toxicol Pathol. 1987;15(2):143-8
references.pmid: 3616399